Physicians' Academy for Cardiovascular Education

Lipids

Do personalized reminders to clinicians result in higher use of high-intensity statins?

3' education - Mar. 23, 2023 - Prof. Salim Virani, MD, PhD

Initiating PCSK9 mAb after ACS: When and how to start?

10' education - Mar. 22, 2023 - Prof. Wouter Jukema, MD, PhD and Prof. Pasquale Perrone-Filardi, MD, PhD

Interesting developments in the field of PCSK9 inhibition

3' education - Mar. 21, 2023 - Prof. Deepak Bhatt, MD

Promising results for oral PCSK9i to proceed to phase 3 trials

3' education - Mar. 8, 2023 - Prof. Christie Ballantyne, MD

Residual inflammatory risk is major driver of CV events and mortality in statin-treated patients

3' education - Mar. 7, 2023 - Prof. Paul Ridker, MD

New evidence-based non-statin treatment to lower LDL-c and CV risk

3' education - Mar. 6, 2023 - Prof. Peter Libby, MD

Assocation between low-carbohydrate high-fat diet and MACE

3' education - Mar. 6, 2023 - Liam Brunham, MD, PhD

Where is bempedoic acid going to fit in?

3' education - Mar. 6, 2023 - Prof. Kausik Ray, MD

Strengths and limitations of phase 3 trial with bempedoic acid

3' education - Mar. 5, 2023 - Prof. Eugene Yang, MD

Protective cardiac effects of statin in patients with lymphoma treated with anthracyclines

3' education - Mar. 5, 2023 - Prof. Marielle Scherrer-Crosbie, MD, PhD

Results of CV outcomes trial with bempedoic acid in statin-intolerant patients

3' education - Mar. 5, 2023 - Prof. Steven Nissen, MD

Guidance for an individualized statin intolerance approach

5' education - Jan. 30, 2023 - Prof. Maciej Banach, MD, PhD

Inflammation as a new target in CV risk reduction

10' education - Dec. 13, 2022 - Prof. Paul Ridker, MD

Findings of a trial with pemafibrate in a contemporary patient population

5' education - Dec. 7, 2022 - Prof. Paul Ridker, MD

Tackling risk reduction in ASCVD: A clinical case

10' education - Dec. 5, 2022 - Prof. Lawrence Leiter, MD

Addressing late-breaking data on triglycerides, fibrates and omega-3FAs

15' education - Nov. 16, 2022 - Prof. Peter Libby, MD, Prof. Gabriel Steg, MD, Prof. Kausik Ray, MD

Effects of a guideline-based approach on achieving LDL-c goals

3' education - Nov. 14, 2022 - Aaram Omar Khader, MD

Low-dose statin lowers LDL-c more than dietary supplements

3' education - Nov. 8, 2022 - Luke J. Laffin, MD

Addressing the unmet needs in LDL-c lowering; what can we expect?

10' education - Nov. 4, 2022 - Prof. John Kastelein, MD, PhD

11 Practical implications of REDUCE-IT

10' education - Oct. 28, 2022 - Prof. Subodh Verma, MD, PhD

Effects of intensive lipid lowering on coronary plaque characteristics

10' education - Oct. 24, 2022 - Prof. Lorenz Räber, MD, PhD & Prof. Stephen Nicholls, MD

The spectrum of therapeutic options: which therapies to consider?

10' education - Oct. 18, 2022 - Prof. Ulf Landmesser, MD

Targeting Lp(a): therapeutic insights and novel developments

10' education - Oct. 12, 2022 - Prof. Erik Stroes, MD, PhD

Real-world evidence with PCSK9i mAb; implications and lessons for current clinical use

10' education - Oct. 12, 2022 - Raul Santos, MD, PhD & Prof. Maciej Banach, MD, PhD

A continuum of multifactorial benefits of icosapent ethyl?

10' education - Oct. 11, 2022 - Prof. Magnus Bäck, MD, PhD

Lp(a) as independent causal risk factor: why should we focus on testing?

10' education - Oct. 11, 2022 - Prof. Florian Kronenberg, MD, PhD

The clinical challenge: a patient with multiple risk factors

10' education - Oct. 7, 2022 - Prof. Erik Stroes, MD, PhD

Targeting Lp(a) in CV risk reduction: where are we now?

10' education - Oct. 5, 2022 - Pia Kamstrup, MD, PhD

Targeting the PCSK9 pathway: where do novel therapies fit in?

10' education - Oct. 5, 2022 - Ann Marie Navar, MD, PhD

Sex-specific differences in the effects of LDL-c on CVD risk

5' education - Oct. 5, 2022 - Arjen Cupido, MD

Short period of very low LDL-c with PCSK9i plus statin associated with prolonged MACE risk reduction

Literature - Mar. 27, 2023 - Schwartz GG et al. - Eur Heart J. 2023

In a new post-hoc analysis of the ODYSSEY OUTCOMES trial, MACE risk was reduced throughout the follow-up period of ~3 years in post-ACS patients who had very low LDL-c levels for 6 months during alirocumab plus statin therapy, followed by statin monotherapy, compared with matched statin-treated patients on placebo only.

ANGPTL3 inhibitor approved by FDA for young children with HoFH

News - Mar. 27, 2023

The FDA has approved the use of the ANGPTL3 inhibitor evinacumab as an adjunct to other lipid-lowering therapies for the treatment of children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH).

Do personalized reminders to clinicians result in higher use of high-intensity statins?

3' education - Mar. 23, 2023 - Prof. Salim Virani, MD, PhD
In the PCDS-Statin trial -a cluster RCT- was investigated whether personalized reminders to primary care clinicians improved the use of high-intensity statins in patients with ASCVD.

ACC.23 In the PCDS-Statin trial -a cluster RCT- was investigated whether personalized reminders to primary care clinicians improved the use of high-intensity statins in patients with ASCVD.

Initiating PCSK9 mAb after ACS: When and how to start?

10' education - Mar. 22, 2023 - Prof. Wouter Jukema, MD, PhD and Prof. Pasquale Perrone-Filardi, MD, PhD
In large RCTs, PCSK9 inhibitors have shown to have great value in patients with ACS, but how do you implement these agents in clinical practice?

In large RCTs, PCSK9 inhibitors have shown to have great value in patients with ACS, but how do you implement these agents in clinical practice?

Beneficial effects of PCSK9i on CV events depend on both hsCRP and Lp(a) levels

Literature - Mar. 21, 2023 - Schwartz GG, et al. - J Am Coll Cardiol. 2022

In this post hoc analysis of the ODYSSEY OUTCOMES trial, the authors demonstrated that the beneficial effects of alirocumab on Lp(a)-associated risk of CV events in patients with ACS are modified by hsCRP.

Interesting developments in the field of PCSK9 inhibition

3' education - Mar. 21, 2023 - Prof. Deepak Bhatt, MD

ACC.23 "The field of LDL-c reduction is very hot", says Deepak Bhatt. He talks about novel ways to lower LDL-c through PCSK9 inhibition, including a new oral agent.

Bempedoic acid reduces hs-CRP, but not fibrinogen and IL-6 in patients with residual inflammatory risk

Literature - Mar. 16, 2023 - Ridker PM, et al. - J Clin Lipidol. 2023

In a secondary biomarker analysis of the CLEAR Harmony trial, bempedoic acid lowered levels of LDL-c and hs-CRP, but not fibrinogen or IL-6, compared with placebo in patients with ASCVD and/or heterozygous familial hypercholesterolemia (HeFH) who had residual inflammatory risk.

Promising results for oral PCSK9i to proceed to phase 3 trials

3' education - Mar. 8, 2023 - Prof. Christie Ballantyne, MD
Prof. Ballantyne briefly discusses the findings of a phase 2b trial with the oral macrocyclic peptide MK-0616, an inhibitor of PCSK9, in patients with hypercholesterolemia.

ACC.23 Prof. Ballantyne briefly discusses the findings of a phase 2b trial with the oral macrocyclic peptide MK-0616, an inhibitor of PCSK9, in patients with hypercholesterolemia.

New oral PCSK9 inhibitor lowers LDL-c in hypercholesterolemia

News - Mar. 8, 2023

ACC.23 Injectable treatments may have poor adoption due to access barriers and the need for repeat injections. An oral PCSK9 inhibitor, MK-0616, was developed and tested in a phase 2b trial.

Residual inflammatory risk stronger determinant of MACE and mortality in statin-treated patients

News - Mar. 7, 2023

ACC.23 In a collaborative analysis of the PROMINENT, REDUCE-IT, and STRENGTH trials, hs-CRP was a better predictor of future MACE, CV death, and all-cause mortality than LDL-c in statin-treated patients with, or at high risk of, atherosclerotic disease.

Centrally controlled individualized reminders improve use of high-intensity statin

News - Mar. 7, 2023

ACC.23 In a multisite-RCT study was examined whether an intervention including individualized reminders sent to primary care clinicians improved use of high-intensity statin in patients with ASCVD.

Residual inflammatory risk is major driver of CV events and mortality in statin-treated patients

3' education - Mar. 7, 2023 - Prof. Paul Ridker, MD
“We as cardiologists have to recognize that time has come to aggressively lower LDL-c, which we are already doing, but we need to add aggressive reduction of inflammation to that”, says Prof. Ridker.

ACC.23 “We as cardiologists have to recognize that time has come to aggressively lower LDL-c, which we are already doing, but we need to add aggressive reduction of inflammation to that”, says Prof. Ridker.